Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC-CIK cells (Fuda Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Fuda Cancer Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
DC-CIK cells are an adoptive cellular immunotherapy consisting of a co-culture of dendritic cells (DCs) and cytokine-induced killer (CIK) cells. CIK cells are a heterogeneous population of effector T cells, primarily CD3+CD56+ cells, generated by the ex vivo expansion of peripheral blood mononuclear cells in the presence of interferon-gamma, anti-CD3 monoclonal antibodies, and interleukin-2. Dendritic cells are professional antigen-presenting cells that, when co-cultured with CIK cells, enhance their tumor-specific cytotoxicity and proliferation by presenting tumor-associated antigens. At Fuda Cancer Hospital in Guangzhou, this therapy is being investigated for the treatment of hepatocellular carcinoma, often as an adjuvant treatment following cryosurgery or in combination with other cell types like γδ T cells, to eliminate residual tumor cells and prevent recurrence.
- Other names
- Dendritic cell-cytokine induced killer cellsDC-CIK immunotherapyDC-CIK therapy
02
Targets
pMHC (Peptide-MHC complex family)PDCD1 (Programmed cell death protein 1 receptor)CD40 (Cluster of differentiation 40 receptor)ULBP (ULBP family)NCR1 (Natural cytotoxicity triggering receptor 1)
Beyond the preview
Go deeper on DC-CIK cells (Fuda Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC-CIK cells (Fuda Cancer Hospital).